Steven Erpelinck BSc. MBA
- bioavailability
- microdosing
- AMS transporters
- permeability
- PBPK modeling
Event
Making confident clinical development decisions at ASCPT
Washington Marriot Wardman Park, Washington DC • 15 Mar 2017 - 18 Mar 2017
Developing a new drug is a lengthy, expensive process. Metabolites in Safety Testing in First-In-Men studies provide valuable information to de-risk clinical development and optimize the toxicological assessment. At the ASCPT annual meeting, from 15-18 March in Washington, TNO will present its capabilities in the field of microtracer AMS studies.
Microtracers can be used to increase the information density in your early clinical trials. The information on metabolites in First-In-Man studies will de-risk the clinical development trajectory because of the 100% certainty of not finding any human unique metabolites at a later stage. TNO is the only organization in Europe with a biomedical Accelerator Mass Spectrometer (AMS) that enables this research.
The focus and experience of TNO in the field of microtracer research extends to:
- Metabolite profiling and identification in First-In-Man studies
- Absolute bioavailability in early clinical development
- Early PK of biologicals (peptides, proteins, ADCs etc) and small molecules using microdosing
- Pediatric PK studies to optimize dosing strategies and increase recruitment rates dramatically
At the ASCPT, TNO will present its capabilities in the field of microtracer AMS studies showing that these studies will accelerate drug development. Advantages of our auto-combustion based AMS in comparison to the conventional graphitization based AMS will be demonstrated. In addition, we will show the strengths of using our simultaneous data acquisition using high resolution MS (for metabolite identification) and AMS (for metabolite quantification) approach.
We look forward to meeting you at our booth, number 40.
Our work
Microtracer AMS: Accelerate your clinical development
De-risk and accelerate drug development with TNO’s exclusive auto-combustion-based AMS technology. Each Phase I, first-in-human (FIH) study can be a MIST and Mass Balance study, for faster, economical... Read more
Our work
Personalized Health: 3d printing of medicines
Formulators within the Pharmaceutical industry are often struggling to achieve sufficient systemic exposure of the drug which is meant to evoke a specific therapeutic effect. 3D printing offers the opportunity... Read more
Events
Email
Contact
Steven Erpelinck BSc. MBA
- bioavailability
- microdosing
- AMS transporters
- permeability
- PBPK modeling